As part of its ongoing campaign to pressure Gilead
Sciences, Inc. and educate the public about the exorbitant price
of HIV/AIDS medications, AIDS
Healthcare Foundation (AHF) today challenged the company over
its price discrimination for its four-in-one HIV drug, Stribild. In the
United States, Gilead charges a yearly wholesale price (WAC) of $28,500
per patient for Stribild while charging only $16,600 in Canada – a
difference of nearly $12,000 per patient. (At present, the US dollar is
worth .99 of Canadian dollar).
“There is no justification for Gilead to continue to charge $28,500 for
Stribild in the U.S. while it is willing to cut the price in Canada and
other countries,” said AHF President Michael Weinstein. “Gilead
has made it loud and clear that without the kind of price controls that
exist in Canada and Europe, its greed and blatant disregard for the
health of its customers—people with HIV/AIDS—will continue undiminished.”
Gilead’s four-in-one AIDS treatment combination, was approved by the
Food and Drug Administration (FDA) in early September and immediately
priced by Gilead at $28,500 per patient, per year, Wholesale Acquisition
Cost (WAC). That price was over 35% more than Atripla, the company’s
best selling combination HIV/AIDS treatment, and made Stribild the
highest priced first line combination AIDS therapy today.
Already this year, on January 1st, Gilead raised the prices
of four key AIDS medications in the U.S. by an average of 6%, including
the price of Atripla,
its best-selling three-in-one combination treatment, the price of which
was increased by 6.9% to a Whole Acquisition Cost (WAC) of $1,878.23 per
patient, per month. The other three HIV/AIDS medications that saw price
hikes are Complera,
which was raised by 5.8% to a WAC of $1,936.53; Emtriva,
by 5.5% to a WAC of $478.45; and Viread,
by 6% to a WAC of $771.39.
In late November, CATIE-News,
an online site which states it is “Canada’s source for HIV and
Hepatitis C information,” reported the Canadian price for
Stribild is $16,600 per patient per year. This is a 42% cost reduction
compared to the $28,500 Stribild costs per patient per year in the US.
This price reduction highlights Gilead's apparent willingness to gouge
the pockets of US taxpayers and government-funded programs like the AIDS
Drug Assistance Program (ADAP) while making price concessions to
countries with sometimes stronger economies than the US.
About AIDS Healthcare Foundation
AIDS Healthcare Foundation (AHF), the largest global AIDS organization,
currently provides medical care and/or services to nearly 200,000
individuals in 28 countries worldwide in the US, Africa, Latin
America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn
more about AHF, please visit our website: www.aidshealth.org,
find us on Facebook: www.facebook.com/aidshealth
and follow us on Twitter: @aidshealthcare.